

The Journal of PHARMACOLOGY

And Experimental Therapeutics

A Publication of the American Society for Pharmacology and Experimental Therapeutics

September 2023

Vol. 386, No. 3

Contents

VIEWPOINT

Could a Nebulized or Dry Powder Inhalation of a Dopamine D1R Agonist Be a Treatment of Idiopathic Pulmonary Fibrosis? 274

Bradley T. Andresen

☐ Dopamine Receptor D1 Is Exempt from Transforming Growth Factor β -Mediated Antifibrotic G Protein-Coupled Receptor Landscape Tampering in Lung Fibroblasts 277

Ashley Y. Gao, Ana M. Diaz Espinosa, Ba Bao N. Nguyen, Patrick A. Link, Jeffrey Meridew, Dakota L. Jones, Daniel F. Gibbard, Daniel J. Tschumperlin, and Andrew J. Haak

MINIREVIEW

Post-Transcriptional and Epigenetic Regulation of Estrogen Signaling 288

Andrea Cignarella, Carlotta Boscaro, Mattia Albiero, Chiara Bolego, and Matthias Barton

CARDIOVASCULAR

☐ Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K_{ATP} Channel Mutations in Intact Cells 298

Jian Gao, Conor McClenaghan, Kenneth A. Matreyek, Dorothy K. Grange, and Colin G. Nichols

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

☐ The CaMKII Inhibitory Peptide AIP Alleviates Renal Fibrosis Through the TGF- β /Smad and RAF/ERK Pathways 310

Xiaocui Feng, Jianfeng Zhang, Runling Yang, Jingya Bai, Bochuan Deng, Lu Cheng, Feiyun Gao, Junqiu Xie, and Bangzhi Zhang

METABOLISM, TRANSPORT, AND PHARMACOGENETICS

☐ Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model 323

Karolina H. Dziejulska, Julie A. Reisz, Ariel M. Hay, Angelo D'Alessandro, and James C. Zimring

NEUROPHARMACOLOGY

Protein Kinase A Is Responsible for the Presynaptic Inhibition of Glycinergic and Glutamatergic Transmissions by Xenon in Rat Spinal Cord and Hippocampal CA3 Neurons 331

Il-Sung Jang, Michiko Nakamura, Kiku Nonaka, Mami Noda, Naoki Kotani, Shutaro Katsurabayashi, Hideaki Nagami, and Norio Akaike

☐ Supplemental material is available at jpet.aspetjournals.org.

About the cover: D1 agonists inhibit fibroblast proliferation and collagen expression. See the article by Gao et al. ([dx.doi.org/10.1124/jpet.122.001442](https://doi.org/10.1124/jpet.122.001442)).